; and (4) in subsection (g), in the matter preceding paragraph (1)— (A) by inserting (including antifungal biological products) after antifungal drug ; and (B) by inserting or prevent after treat . (b) Effective date The amendments made by subsection (a) shall apply with respect to applications for the approval of biological products under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) submitted on or after the date of the enactment of this Act. (c) Updated guidance Not later than one year after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall update Qualified Infectious Disease Product Designation Questions and Answers Guidance for Industry issued in January 2018, to implement the amendments made by subsection (a). 7. Priority review to encourage treatments for endemic orphan fungal diseases Subchapter B of chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360aa et seq.) is amended by adding at the end the following new section: 529B. Priority review to encourage treatments for endemic orphan fungal diseases (a) Definitions In this section: (1) Endemic orphan fungal disease The term endemic orphan fungal disease means a disease, such as coccidioidomycosis, that— (A) is caused by a fungus; (B) primarily occurs in certain limited geographic regions; and (C) is a rare disease or condition (as that term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bb(a)(2) )). (2) Endemic orphan fungal disease drug application The term endemic orphan fungal disease drug application means an application that— (A) is a human drug application for a drug intended for use— (i) to prevent or treat harm from an endemic orphan fungal disease; or (ii) to cure an endemic orphan fungal disease; (B) the Secretary determines eligible for priority review; (C) is approved after the date of enactment of this section